Advertisement

Advertisement

MBRX Stock Latest News

Moleculin Highlights Annamycin Cardiac Safety Data at ASCO

Company AnnouncementsMoleculin Highlights Annamycin Cardiac Safety Data at ASCO

Moleculin Biotech Releases Updated Investor Information Presentation

PremiumCompany Announcements

Moleculin Biotech Releases Updated Investor Information Presentation

6d ago

Moleculin Highlights Annamycin Cardiac Safety Data at ASCO

PremiumCompany Announcements

Moleculin Highlights Annamycin Cardiac Safety Data at ASCO

9d ago

PremiumRatings

Buy Rating Reiterated on Moleculin Biotech as MIRACLE Trial Progress and Safety Profile Support Unchanged $22 Price Target

17d ago

Buy Rating Reiterated on Moleculin Biotech as MIRACLE Trial Progress Supports Unchanged $10 Price Target

PremiumRatings

Buy Rating Reiterated on Moleculin Biotech as MIRACLE Trial Progress Supports Unchanged $10 Price Target

17d ago

Moleculin Biotech expects first unblinding of MIRACLE trial data by June 30

PremiumThe FlyMoleculin Biotech expects first unblinding of MIRACLE trial data by June 30

18d ago

Moleculin Nears First Unblinding in Pivotal MIRACLE Trial

Company Announcements

Moleculin Nears First Unblinding in Pivotal MIRACLE Trial

19d ago

Moleculin announces publication on cardiac safety profiloe of annamycin

The Fly

Moleculin announces publication on cardiac safety profiloe of annamycin

19d ago

Moleculin highlights favorable cardiac safety data for Annamycin

PremiumCompany Announcements

Moleculin highlights favorable cardiac safety data for Annamycin

19d ago

Moleculin Biotech issued liposomal Annamycin patent in Hong Kong

PremiumThe Fly

Moleculin Biotech issued liposomal Annamycin patent in Hong Kong

23d ago

Moleculin Secures New Hong Kong Patent for Annamycin

PremiumCompany Announcements

Moleculin Secures New Hong Kong Patent for Annamycin

23d ago

Moleculin Highlights Promising Preclinical Data for L-ANN

PremiumCompany Announcements

Moleculin Highlights Promising Preclinical Data for L-ANN

1M ago

Moleculin Biotech Stockholders Approve Warrant Share Issuance

PremiumCompany AnnouncementsMoleculin Biotech Stockholders Approve Warrant Share Issuance

2M ago

Moleculin Biotech management to meet with Maxim

The Fly

Moleculin Biotech management to meet with Maxim

2M ago

Moleculin Biotech files to sell 6.37M shares of common stock for holders

The Fly

Moleculin Biotech files to sell 6.37M shares of common stock for holders

2M ago

Moleculin Biotech announces enrollment milestone in MIRACLE trial

PremiumThe Fly

Moleculin Biotech announces enrollment milestone in MIRACLE trial

2M ago

Moleculin Advances MIRACLE Trial, Prepares Interim AML Readout

PremiumCompany Announcements

Moleculin Advances MIRACLE Trial, Prepares Interim AML Readout

2M ago

Moleculin Biotech: Attractive Risk/Reward Ahead of Pivotal Annamycin Phase 3 Readout Supports Buy Rating and $10 Target

PremiumRatings

Moleculin Biotech: Attractive Risk/Reward Ahead of Pivotal Annamycin Phase 3 Readout Supports Buy Rating and $10 Target

2M ago

Moleculin Biotech Updates Investors with New Corporate Presentation

PremiumCompany Announcements

Moleculin Biotech Updates Investors with New Corporate Presentation

2M ago

Moleculin Biotech reports FY25 EPS ($28.42) vs. ($189.14) last year

PremiumThe FlyMoleculin Biotech reports FY25 EPS ($28.42) vs. ($189.14) last year

2M ago

Moleculin Biotech sees cash runway into 3Q26

The Fly

Moleculin Biotech sees cash runway into 3Q26

2M ago

MBRX Earnings this Week: How Will it Perform?

Pre-Earnings

MBRX Earnings this Week: How Will it Perform?

2M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >